0.47] and 0.85% [95% CI 1.03
Reported side effects are generally mild, but long-term safety, drug interactions, and product quality remain open questions, which is why medical supervision matters
Comparison of 2-year weight loss trends in behavioral treatments of obesity: diet, exercise, and combination interventions
Egyb gygyszerek s a Saxenda Felttlenl tjkoztassa kezelorvost, gygyszerszt vagy a gondozst vgz egszsggyi szakembert a jelenleg vagy nemrgiben szedett, valamint szedni tervezett egyb gygyszereirl
[1] [2] These medicines include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro), which is a dual GIP/GLP-1 receptor agonist
The comparative analysis revealed that semaglutide use is associated with a significantly higher risk of vision impairment compared to other GLP-1 RAs